Therapy Areas: Oncology
CARsgen Therapeutics Holdings names new president of CARsgen Therapeutics Corporation
18 January 2022 -

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a China-based company mainly focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumours, announced on Monday that it has named Richard John Daly as its new president of CARsgen Therapeutics Corporation, a subsidiary of the company in the United States.

Daly is to report to Dr Zonghai Li, founder, chairman of the board, CEO, CSO of CARsgen Therapeutics Holdings Limited. He is to head the CARsgen United States team for its international business activities outside of China, including clinical development, CMC operation, business development, commercialisation, investor relations and public relations. He will also contribute to the company's overall growth strategies and business planning, supporting it to develop more innovative cell therapies for cancer patients worldwide.

Daly has around 30 years of experience in the pharmaceutical industry, including leadership positions in multi-national corporations and biotech companies. He has held the position of chief operating officer of Beyond Spring Inc. (NASDAQ: BYSI). He has served as chief executive officer, president and chairman of Neuralstem Inc. (NASDAQ: PALI). He has held the position of president of AstraZeneca's United States Diabetes subsidiary. He has held various positions including executive vice president at Takeda Pharmaceutical North America and the senior vice president of marketing at TAP Pharmaceuticals. Presently, he is serving as the director of Catalyst Pharmaceuticals (NASDAQ: CPRX) and Opiant Pharmaceuticals (NASDAQ: OPNT).

Login
Username:

Password: